Matt Maguire Email

VP, Market Access, Trade & Patient Services . Oyster Point Pharma

Current Roles

Employees:
189
Revenue:
$17.9M
About
Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The companyᅢᄁ¬ツᆲ¬トᄁs initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board. For more information visit oysterpointrx.com and follow on Twitter at @OysterPointRx.
Oyster Point Pharma Address
700 Alexander Park #301
Princeton, NJ
United States
Oyster Point Pharma Email

Past Companies

Oyster Point Pharma, Inc.Vice President, Market Access, Trade & Patient Services
NovartisExecutive Director, Marketing & Patient Services
TakedaSenior Director, Ophthalmic Marketing, Market Access & Patient Services

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.